反応式
[C:1]1([CH2:7][C:8]([OH:10])=O)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.C1C=CC2N(O)N=NC=2C=1.CCN(C(C)C)C(C)C.[NH2:54][CH2:55][C:56]1[O:60][C:59]([C:61]2[CH:66]=[CH:65][C:64]([C:67]3[C:72]([CH3:73])=[CH:71][CH:70]=[C:69]([C:74]([NH:76][CH:77]4[CH2:79][CH2:78]4)=[O:75])[CH:68]=3)=[CH:63][CH:62]=2)=[N:58][N:57]=1>CN(C=O)C>[CH:77]1([NH:76][C:74]([C:69]2[CH:68]=[C:67]([C:64]3[CH:65]=[CH:66][C:61]([C:59]4[O:60][C:56]([CH2:55][NH:54][C:8](=[O:10])[CH2:7][C:1]5[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=5)=[N:57][N:58]=4)=[CH:62][CH:63]=3)[C:72]([CH3:73])=[CH:71][CH:70]=2)=[O:75])[CH2:79][CH2:78]1参加物
7
反応物 5
生成物 1
試薬・触媒・溶媒 1
実験手順
Phenylacetic acid (12 mg) and HATU (33 mg) in DMF (1 ml) were stirred for 10 minutes at room temperature. To this solution was added HOBt (11.6 mg), DIPEA (.0.45 ml) and 4′-[5-(aminomethyl)-1,3,4-oxadiazol-2-yl]-N-cyclopropyl-6-methyl-1,1′-biphenyl-3-carboxamide (Example 53) (30 mg) in DMF (2 ml) and the reaction stirred at room temperature for 18 hours. The solvent was evaporated under vacuum and the residue dissolved in DMSO (0.25 ml), methanol (0.25 ml) was added and the precipitate produced isolated by filtration to give N-cyclopropyl-6-methyl-4′-(5-{[(phenylacetyl)amino]methyl}-1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-3-carboxamide.
後処理
- customThe solvent was evaporated under vacuum
- dissolutionthe residue dissolved in DMSO (0.25 ml)
- additionmethanol (0.25 ml) was added
- customthe precipitate produced
- customisolated by filtration
出典と根拠
- ORDレコード
- ord-952287615a4c4aa1a2e947ff07f4271d
- 出典データセット
- uspto-grants-2008_09
- 特許番号
- US07425555B2
関連ノート
読み込み中…